𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hepatitis B virus-DNA in the serum of patients followed-up longitudinally with acute and chronic hepatitis B

✍ Scribed by Dr. T. Moestrup; B. G. Hansson; A. Widell; J. Blomberg; E. Nordenfelt


Publisher
John Wiley and Sons
Year
1985
Tongue
English
Weight
483 KB
Volume
17
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis


Sera from 79 patients with acute self-limiting hepatitis, 17 patients with acute hepatitis B evolving into chronic HBsAg carriership, and 43 chronic HBsAg carriers without a history of acute hepatitis were analyzed for presence of hepatitis B virus (HBV)-DNA by a molecular hybridization technique. In acute self-limiting hepatitis, HBV-DNA was cleared within a few weeks after the onset of clinical symptoms. The longest period of DNA positivity observed in this group was 42 days. In 29 of 52 patients HBV-DNA was cleared before HBeAg disappeared. Among 17 patients who became chronic HBsAg carriers, HBV-DNA was present for more than 6 months in all but one. Most of the HBsAg carriers eventually cleared HBV-DNA. The DNA clearance frequently preceeded the conversion of HBeAg to anti-HBe. Thus, in many patients there was a transitional period with HBeAg but without HBV-DNA. HBV-DNA was found to be a better index of impending chronicity than HBeAg since persistence of HBeAg for more than 42 days was noted in 10% of the patients who nevertheless cleared HBsAg within 6 months. By that time all those patients had turned negative for HBV-DNA. On the other hand, in 16 of the 17 patients who became chronic carriers of HBsAg, HBV-DNA as well as HBeAg persisted for more than 6 months. The present results also suggest that infectivity in acute hepatitis B is a feature mainly of the presymptomatic and early symptomatic period.


📜 SIMILAR VOLUMES


Hepatitis B virus DNA in serum from pati
✍ Kim Krogsgaard; Peter Kryger; Jan Aldershvile; Poul Andersson; Christian Brechot 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB 👁 1 views

Sera from 77 consecutive patients with acute type B hepatitis were examined for hepatitis B virus DNA (HBV DNA) by a spot hybridization method. The median follow-up time was 8 months (range, 1 week to 3 years). HBV DNA was detected in 26 (34%) patients on admission to the hospital. A significant pos

Leucocyte hepatitis B virus DNA in acute
✍ F. Davison; G. J. M. Alexander; Ch. Anastassakos; E. A. Fagan; Roger Williams 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 444 KB 👁 1 views

In the present study we have investigated 53 patients with a spectrum of acute and chronic hepatitis B virus (HBV) infection for the presence of leucocyte HBV-DNA with the aid of molecular techniques. HBV-DNA was detected in peripheral blood mononuclear cells of 31 of 45 (69%) of chronic HBsAg carri

Hepatitis B infection of the liver in ch
✍ Luisa Fernanda Mariscal; Elena Rodríguez-Iñigo; Javier Bartolomé; Inmaculada Cas 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 327 KB 👁 2 views

## Abstract Hepatitis B virus (HBV) DNA may persist in the liver in the absence of serum HBV–DNA after a self‐limited acute hepatitis B. This may also occur in patients with chronic hepatitis C virus (HCV) infection but its prevalence and its impact on liver histology is unknown. HBV–DNA was tested

Quantitation of covalently closed circul
✍ Danny Ka-Ho Wong; Man-Fung Yuen; HeJun Yuan; Simon Siu-Man Sum; Chee-Kin Hui; Je 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 236 KB 👁 1 views

This study examined a signal amplification assay, the Invader assay, for the quantitation of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) in liver biopsies and sera. DNA was extracted from liver biopsy and serum samples were collected from 16 hepatitis B e antigen (HBeAg)-positive

Efficacy of lamivudine in patients with
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60

Serum hepatitis B virus-DNA cutoff level
✍ George V. Papatheodoridis; Emanuel K. Manesis; Spilios Manolakopoulos; Athanasio 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB 👁 2 views

Commitment of bone marrow cells to hepatic stellate cells in mouse. J Hepatol 2004;40:255-260. 6. Kisseleva T, Uchinami H, Feirt N, Quintana-Bustamante O, Segovia JC, Schwabe RF, et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol 2006;45:429-438. 7. Magnes